Search
Cullinan Therapeutics Inc
CGEMAdd to Watchlist
16.500USD
-1.020-5.82%
Close 07-31 16:00（ET）Quotes delayed by 15 min
1.01BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-31The current earnings forecast score of Cullinan Therapeutics Inc is 9.08, ranking 15 out of 385 in the Biotechnology & Medical Research industry. The average price target is 28.00, with a high of 53.00 and a low of 22.00.
Analyst Rating
Based on
13
analysts
Strong Buy
Current Rating
39.182
Target Price
+137.47%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Cullinan Therapeutics Inc
CGEM
13
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
Kymera Therapeutics Inc
KYMR
24
Insmed Inc
INSM
23
1
2
3
...
99
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Cullinan Therapeutics Inc's price target?
Analysts forecast that Cullinan Therapeutics Inc's price target is USD 28.00, with the highest forecast at USD 53.00 and the lowest forecast at USD 22.00.
How have Cullinan Therapeutics IncCGEM's recent earnings per share performed?
The market expectation was USD -0.82, while Cullinan Therapeutics IncCGEM's earnings per share (EPS) for the previous quarter was USD -0.86. EPS for the next quarter is expected at USD -0.81.
What is the analyst rating for Cullinan Therapeutics Inc?
Based on the ratings of Cullinan Therapeutics Inc's stock from 13 analysts, most analysts support a STRONG BUY trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as STRONG BUY. Please note that this is not trading advice. You still need to conduct your own analysis.